Top investor slashes Moderna’s valuation as company struggles to live up to its own hype https://www.statnews.com/2017/06/28/moderna-writedown/ Biotech’s biggest unicorn just took a billion-dollar haircut. One of Moderna Therapeutics’ largest investors slashed its assessment of the company’s value by 34 percent, a painful write-down that comes as the ambitious young biotech struggles to retain talent and make good on its lofty promises to upend the drug industry.